ATOMO DIAGNOSTICS LIMITED — Capital/Financing Update 2023

Apr 4, 2023

==> picture [75 x 73] intentionally omitted <==

ASX Announcement

5[th] April 2023

Atomo signs A$1.9m[1] take-or-pay agreement with Viatris for HIV SelfTesting in South African private sector

SYDNEY, Australia, 5th April, 2023 – Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce it has signed a ‘take-or-pay’ agreement with long term partner Viatris for its HIV Self-Test for the South African private market.

Under the agreement, Viatris has committed to purchasing a minimum quantity of tests each year over a 5-year period, with a total value to Atomo of A$1.9m[1] . This new agreement for the private sector market is considered to be material from a growth perspective and is separate and additional to the existing agreement between the parties for HIV Self-Test public health markets in South Africa and other countries.

Atomo’s CEO John Kelly said “In this post-COVID environment we are seeing a return to growth for HIV testing and the emergence of ‘consumer-initiated testing’ as a key driver of growth in the diagnostic market. It is pleasing to be able to expand our partnership with Viatris to the South African private sector market, where there is strong demand and improved pricing relative to global health channels. Viatris has an established consumer health business in South Africa and will be leveraging this network to expand sales of the Atomo designed and manufactured HIV self-test into pharmacies and other private sector channels.”

The agreement, which is subject to standard termination provisions, is effective immediately, with Viatris indicating its intention to place an initial order imminently. Following the entry into the new agreement with Viatris, Atomo has terminated its distribution agreement with Iyeza Health which covered the sale of its HIV Self-Test devices in the South African private sector and conferred on Viatris an exclusive right to promote and sell those products in that market. It is noted that the Iyeza Health agreement was disclosed as a material agreement in the Company’s Supplementary Prospectus dated 31 March 2020.

1 The agreement is denominated in USD. $1.9m is based on a current AUD:USD exchange rate of 1.50:1.00

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684

==> picture [75 x 73] intentionally omitted <==

This announcement was authorised by the Managing Director & CEO.

For more information, please contact:

John Kelly Atomo Diagnostics john.kelly@atomodiagnostics.com Phone: +61 401 922 279

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnostics.com

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684